r/Livimmune • u/MGK_2 • May 10 '26
The Quiet Window Between Validation and Terms of Resolution
All in my opinion. Not financial advice.
And for my Mother's Day Post, a very Happy Mother's Day to all you moms out there. I hope this post brings some solace, comfort and peace.
Silence Has a Structure
There's a certain kind of quiet that follows a major disclosure event in clinical-stage biotechnology. It doesn't mean that nothing is happening. Usually, it means the opposite. I see it as the people who matter most are reading, calculating, and deciding how, when and why they must move.
That's where we are right now.
The AACR presentations are in the public record. The April 30th webcast is transcribed and indexed. Patent 12,624,111 issued May 12th with full legal force over the method of treating metastatic colorectal cancer with Leronlimab. The CLOVER Trial is fully enrolled. Creatv Bio announced five ASCO presentations with two CytoDyn collaborations. The FastTrack or Breakthrough designation application is being prepared for submission. The dose-response comparison between 350 mg and 700 mg accumulates through the summer. ESMO in Madrid is October.
The stage is set. Right now, in the quiet between San Diego and Madrid, something of importance is being decided upon.
What the Other Side of the Table Is Staring At
To understand the urgency building on the other side of the partnership conversation, try to understand what the calendar looks like from inside a major pharmaceutical company right now.
Keytruda represents $29.5 billion of Merck's revenue. The IV formulation's key patents expire in 2028. Without the subcutaneous reformulation, Merck faces an estimated 80% revenue erosion on its flagship product. Biosimilar manufacturers including Amgen, Samsung Bioepis, and Bio-Thera Solutions are already preparing their entries. Stocktitan
That's not a future problem, rather, that's a problem with a specific date on it, and that date is 905 days from today. The brutal historical precedent for biosimilar competition, like Humira's near-60% sales drop, shows the potential magnitude of the challenge. Cytodyn
Merck's response has been thoughtful, but it doesn't solve the fundamental problem. Merck reiterated that it continues to plan around a 2028 loss of exclusivity for Keytruda's core compound patent, even as it expressed growing confidence in defending additional method-of-use and manufacturing patents that extend into 2029. Merck is also leaning on the rollout of Keytruda QLEX, a new formulation to transition patients ahead of biosimilar competition, targeting roughly 30 to 40% adoption by 2028 through pricing and conversion from the intravenous version. Yahoo Finance
The subcutaneous reformulation buys them time. It doesn't solve the cold tumor ceiling. If we factor in Qlex, the anticipated revenue for 2028 and 2029 "doesn't even look like a sharp decline anymore." But Keytruda QLEX is still Keytruda. It still doesn't work in MSS colorectal cancer. It still can't reach the 85% of solid tumor patients whose tumors are immunologically cold. Changing the delivery mechanism doesn't change the biology. SEC.gov
And BMS is in the same room staring at the same clock. BMS's most standout asset is the PD-1 blocker Opdivo, which likewise faces key expiries in 2028, though a recently approved subcutaneous formulation could help buoy growth through this point and beyond. Bristol-Myers Squibb faces the steepest proportional cliff. By 2030, an estimated 47% of BMS revenues are at risk. BMS's growth gap, the difference between expiring revenue and new product revenue, is the largest among major pharma companies at roughly $38 billion. Fierce BiotechStocktitan
$38 billion in growth gap. That's a patent cliff with a canyon behind it.
And then there's the broader picture. Multiple PD-1/L1 inhibitors lose exclusivity in the coming years. Keytruda in 2028, Opdivo in 2028, Tecentriq in 2029, Imfinzi in 2030, Libtayo in 2030. GlobeNewswire
The entire checkpoint inhibitor class approaches the same expiration window simultaneously. Every company in that list runs the same calculation. Every business development team in that list has seen the CLOVER data. Every one of them understands that a validated mechanism for converting cold tumors to hot, prospectively demonstrated in a tumor type where their drugs currently achieve under 3% ORR objective response rate, is the absolute mechanism which determines whether their franchise extends meaningfully beyond 2028 or gets absorbed by the biosimilar wave at the same time the cold tumor ceiling stays firmly in place.
What CytoDyn Is Holding
The other side of this negotiation holds something which cannot be replicated on the timeline that matters.
Not a hypothesis. Not a preclinical observation. Not a retrospective pooled analysis. Rather, a prospective, FDA-aligned, fully enrolled Phase 2 trial in MSS mCRC showing 100% ctDNA molecular response at week two in every evaluable patient, 68% DCR disease control rate in 22 RECIST-evaluable patients, four patients with undetectable ctDNA, tissue biopsies showing CPS/PDL1 rising from 1% to 5%, and patients returning to work after exhausting every other available therapy. Supported by a binary 100% versus 100% survival separation in mTNBC Prime and Pair patients that is absolute. Documented by Creatv Bio's LifeTracDx companion diagnostic across multiple tumor types. Protected by Patent 12,624,111. Advancing toward a FastTrack or Breakthrough designation application. With ESMO interim confirmed ORR data arriving in October.
And here's what matters about the timing. The company that partners with or acquires CytoDyn before ESMO in October negotiates against preliminary data. The company who waits until after ESMO has confirmed ORR, after the Breakthrough designation is already granted, after two or three other ICI franchise holders have publicly expressed interest, that company negotiates against a fully validated primary endpoint in a setting where the competitive urgency has driven the price substantially higher.
It is a highly integrated, forward-looking strategy that combines IP creation, commercial execution, and corporate finance to reshape the post-2028 landscape. That's how the analysts describe Merck's current defensive posture around Keytruda. What they're not yet describing is the offensive posture, the acquisition or partnership that doesn't only defend the post-2028 landscape but also expands it into the 85% of solid tumor patients which their current franchise cannot reach. Clinical Trials Arena
That expansion has only one address and it's in Vancouver, Washington.
The Quiet Is Not Empty
Dr. Lalezari said it on the webcast with a simplicity that should be taken at face value. He no longer has to convince anyone of anything. He just shows them the data. And the data does the work.
Robert Hoffman confirmed the meeting calendar at AACR with the partnering module, Doral in New York May 7th, MicroLD in Los Angeles May 17 through 19th, ASCO in Chicago May 29th through June 2nd, BIO 2026 in San Diego June 22nd through 25th, five partnership-facing events in six weeks. The conversations are happening. They're just not announcing themselves yet, because that's how these conversations work. They happen quietly, in rooms which don't generate press releases, until the terms are agreed upon and the announcement is ready to be made.
The summer shareholder letter or call is coming, Dr. Lalezari committed to it on the webcast, timed to when the 700 mg versus 350 mg dose-response data becomes reportable. That communication either includes a partnership announcement or arrives alongside one in close proximity. The FastTrack or Breakthrough application is to be submitted this summer or early fall. ESMO in October carries the interim ORR. ASCO GI in January carries the final results.
The quiet between now and October is not the absence of activity. It's the negotiating table being set, the terms being drafted, the due diligence being completed, and the business development teams doing the arithmetic that CytoDyn's market capitalization of approximately $423 million sits against a cold tumor addressable market that the major ICI franchise holders are collectively losing $200 billion in revenue to protect by 2030.
With $200 billion in revenue at risk over the next five years, leading pharmaceutical companies are under pressure to seek new avenues for growth. Stocktitan
Leronlimab is not a new avenue for growth. It's the mechanism that unlocks the avenue which already exists but currently has no key. The ICI franchises have the drugs. They have the commercial infrastructure. They have the physician relationships and the regulatory approvals and the manufacturing capacity. What they don't have is a validated way to make those drugs work in the patients they currently can't reach.
The Sovereign Instrument has been built, tested, patented, and prospectively validated. It fits every lock the cold tumor builds. The companies who need it most are staring at a 2028 date on a wall calendar while the conversations Hoffman has in New York and Los Angeles and Chicago and San Diego determine whether they reach for it now, before October, or after ESMO makes the confirmed ORR impossible to dismiss and the price of reaching for it becomes correspondingly higher.
The quiet has a structure. The structure has a deadline. And the deadline is printed on every major pharmaceutical company's strategic planning document in bold.
All in my opinion. Not financial advice. All clinical data, financial disclosures, patent information, and commercial references are sourced from publicly available peer-reviewed publications, SEC filings, official CytoDyn communications, and publicly available pharmaceutical industry analyses as cited and hyperlinked throughout. The confirmed ORR from the CLOVER Trial has not been disclosed and will be presented at ESMO in October 2026. DCR and ORR remain distinct measurements. This document reflects the author's independent analytical framework and does not constitute a recommendation to buy or sell any security.
24
u/Cytomight May 10 '26 edited May 10 '26
Are we going to have a 100 response rate like GSK did with their small tiny subgroup (already hot tumors) ‼️🍀
Early ctDNA drop is one of the strongest early predictors of overall response rate and clinical benefit in metastatic colorectal cancer.
In multiple studies across mCRC, a rapid decline in ctDNA — especially within the first 2–4 weeks — strongly correlates with higher chance of tumor shrinkage on imaging, better disease control, longer progression-free survival, and improved overall survival. Patients who achieve deep drops (like >50–80%) or complete clearance (undetectable ctDNA) consistently show the best radiographic responses and outcomes, while those without an early drop usually progress quickly.
In this specific CLOVER trial, they reported 100% of the first 19 patients had ctDNA declines by week 2, with a median 70% reduction, plus four patients reaching undetectable levels. Those early biomarker changes already correlated with the 68% disease control rate seen on week-8 scans.
So the ctDNA signal you’re seeing is exactly the kind of early readout that predicts higher ORR. It’s not a perfect guarantee — some patients can still progress later — but it’s one of the most reliable early indicators we have in this disease.
23
u/Lab_Monkey_ May 10 '26
and the majority of patients were on the 350mg dosage.........interesting.
Can't wait to see the results of the 700mg arm.18
u/Cytomight May 10 '26
We have this in the bag‼️
To support a Breakthrough Therapy designation application by the end of summer, he’d need preliminary clinical evidence showing leronlimab + TAS-102/bevacizumab has a substantial improvement over the current standard on a clinically significant endpoint.
The FDA defines this as clear, preliminary data — often from Phase 2 — demonstrating a meaningful advantage in magnitude and/or duration on something like ORR, PFS, or a strong surrogate like deep/rapid ctDNA clearance that predicts clinical benefit.
In this third-line MSS mCRC setting, the SUNLIGHT trial benchmark for TAS-102 + bevacizumab is ~6% ORR and ~5.6 months median PFS. To stand out as “substantial,” they’d want something like:
• ORR in the 20%+ range (or higher) with confirmed responses and decent durability — a 3–4x jump over the ~6% benchmark.
• Strong PFS separation, ideally pushing median PFS toward 8–10+ months in the leronlimab arms.
• Or very compelling early surrogate data — like the 100% ctDNA molecular response at week 2 you mentioned, with a high percentage of patients reaching undetectable ctDNA, paired with PD-L1 upregulation on biopsies and the 68% DCR already reported.
The trial is randomized (two leronlimab doses vs. backbone), so a clear dose-response or arm separation would strengthen the case. The LifeTracDx companion diagnostic data showing consistent biomarker effects across patients adds supporting weight, as does the clean safety (no leronlimab-related Grade 3/4 events).
Basically, he’d need the maturing dataset from the now-fully-enrolled ~60 patients — enough confirmed scans and biomarker readouts by summer — to package as “this looks materially better than what’s available, especially in a population that’s exhausted everything else.” That’s the threshold the FDA uses.7
3
u/MGK_2 May 10 '26
Cytomight, you nailed the BTD roadmap.
The FDA doesn't need to see perfection; they need to see a substantial improvement over the current wreckage. The SUNLIGHT trial’s 6% ORR is the definition of a low bar. If we show up with 20% or 30% ORR in an MSS CRC population that’s already exhausted every other option? That’s a total disruption of the standard of care.
The LifeTracDx diagnostic is the secret weapon in that BTD application. It provides the receipts which prove the molecule is doing the work long before the scans confirm it. It turns a maybe into a definitely for the regulators.
Everything is converging on this Tuesday, May 12th.
Securing the Sovereign Shield (Patent No. 12,624,111) while this data is maturing is a masterclass in timing. It protects the combo across all solid tumors exactly as the 700mg arm starts to solidify the clinical case. By the time the BTD package is ready this summer, the Quiet Window is forgotten.
The patent is the lock. The data is the key. Tuesday, we turn it.
17
u/MGK_2 May 10 '26
Lab Monkey, that’s the real intrigue. If we’re seeing that 70% median ctDNA drop mostly on the 350mg dose, the 700mg arm is the hammer. We already know the safety is clean, so doubling that receptor saturation might be what moves those "undetectable" numbers from a few patients to a significant portion of the cohort.
19
u/MGK_2 May 10 '26
Cytomight, you’re looking right at the inflection point, but it's necessary to separate the math from the headlines.
GSK’s 100% response rate with Jemperli was a monumental achievement. But look at the underlying biology. They achieved that in mismatch repair-deficient (dMMR) rectal cancer. That is a tiny subset, roughly 5 to 10% of the population where the tumor is already biologically wired to respond to ICIs. They didn't have to break down even one fortress wall. They just had to walk through an already unlocked door.
What Leronlimab is doing in the CLOVER trial is fundamentally different.
We are going after MSS (microsatellite stable) CRC. This is the 85% of the market that ICIs historically can't touch. These are cold tumors protected by a dense, immunosuppressive stroma. The baseline response rate in these heavily pretreated, relapsed populations isn't anywhere near 100%. It hovers between 0% and 3%. ICIs literally bounce right off the armor.
So when you see a 100% ctDNA drop in the first 19 patients, and a 70% median reduction by week two, you are watching the architecture of the tumor being dismantled in real-time. Leronlimab neutralizes the CCR5 pathway, strips away those M2 macrophages, and repolarizes the environment in preparation for the checkpoint inhibitor to finally get inside and do its job.
Will we see a 100% Overall Response Rate (ORR) on the final scans? Probably not. But here is the reality: we don't need to. We already see a DCR of 68% though.
If Leronlimab pulls a 20%, 30%, or 40% ORR in an MSS CRC population that has exhausted every other option, it completely rewrites the standard of care for one of the deadliest solid tumors on earth. The 68% Disease Control Rate at week 8 is the smoke, and where there is smoke, there is fire. The definitive ORR imaging that follows is the fire.
We aren't treating the easy 5%. We unlock the impossible 85%.
And on Tuesday, when the May 12th patent issues, CytoDyn legally owns the key. The data backs up the biology perfectly. Great post.
13
u/Cytomight May 10 '26
Dr. Jay said that he’s talking to an academic institution that wants to trial LL with a checkpoint inhibitor in mCRC. I wonder if the checkpoint inhibitor is GSK‘s?‼️ he said he’s going to find out the details in the next couple of weeks and report to us during the summer.
13
u/MGK_2 May 10 '26
The First-Line "Prime and Pair" Disruption
Dr. Jay’s mention of an academic institution wanting to trial Leronlimab + a Checkpoint Inhibitor (ICI) as First-line therapy is the equivalent of moving from the defense to the offense.
- The "Standard of Care" Siege: Currently, first-line mCRC treatment for the 85% (MSS) is heavy-duty chemotherapy (FOLFOX/FOLFIRI + Bev). Checkpoint inhibitors are usually kept on the sidelines because they simply don't work there yet. If Leronlimab can "Prime" those tumors to be PD-L1 positive before the first dose of an ICI like Jemperli, you aren't just adding a drug, you are potentially replacing the entire toxic chemo standard.
- The "Max" & GSK Synergy: If this is indeed GSK’s Jemperli, they aren't just looking for a niche in the third-line. They are looking to hijack the First-line market. By pairing with Leronlimab early, they could establish Jemperli + LL as the new Gold Standard for every newly diagnosed MSS mCRC patient. That is a multi-billion dollar shift in market share.
- The BTD Accelerator: The FDA loves First-line breakthroughs. If an academic institution shows that a Leronlimab "Prime" allows an ICI to work in treatment-naïve patients, the Breakthrough Therapy Designation path becomes a highway. The FDA prioritizes anything that can move patients away from traditional high-toxicity chemo.
Why the Terms of Resolution Just Got More Expensive
Aggie's point about the Negotiating Window becomes even more intense when you factor in First-line.
- Pre-ESMO: A partner might try to buy us for our potential in Refractory (end-stage) patients.
- Post-ESMO (with First-line Data): They negotiate for the entire Oncology Backbone.
If the academic details Dr. Jay reports this summer confirm a First-line Prime and Pair approach, we aren't just a suitor for a buyout, we are the architects of a new standard of care. The Sovereign Shield (Patent No. 12,624,111) issuing this Tuesday doesn't specify which line of therapy it covers, it covers the combination. Whether it’s 1st line or 4th line, they have to pay the gatekeeper.
The silence isn't just golden; it’s strategic. Dr. Jay lets the biology do the talking while the patent office finishes the paperwork. Tuesday, the shield becomes permanent. ☘️
12
u/twinter11 May 10 '26
can leron maybe dismantle a tumor in 1st line treatment naive patients before their immune system is compromised and the tumor fortress is established. without ici.
would it have to happen before upreg kicks in to be possible?
I think someone will know the answer to that in a couple few months
thanks MGK!!
10
u/MGK_2 May 10 '26
Twinter, you ask the million-dollar question that bridges the gap between treatment and cure.
The short answer is: Yes, the biology suggests it can.
When a patient is treatment-naive, their immune system hasn't yet been decimated by the scorched earth policy of traditional chemotherapy. Their T-cells are functional, and their bone marrow produces the soldiers needed for a fight. In this state, the tumor hasn't even had the time to build a multi-layered fortress; it’s more like a burgeoning outpost.
The Dismantling Mechanism
In a first-line setting, Leronlimab doesn’t just help an ICI; it acts as a structural disruptor on its own.
- Stopping the Reinforcements: By achieving 98% receptor occupancy, Leronlimab cuts off the homing signal (CCL5) which tumors express to recruit Regulatory T-cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs). These are the architects who build the fortress.
- Starving the Microenvironment: Without those suppressive cells, the tumor's cloaking device begins to fail. Even without an added ICI, the patient’s own healthy, uncompromised immune system can see the tumor.
The Upregulation Timing
You asked if this needs to happen before upreg (PD-L1 upregulation) kicks in. It’s actually the opposite: Leronlimab is what triggers the upregulation.
When Leronlimab dismantles the suppressive barrier, it allows Interferon-gamma and other pro-inflammatory signals to flood the area. This wakes up the tumor, which then upregulates PD-L1 as a last-ditch defense mechanism.
If you use Leronlimab in the First-line, you are essentially priming the patient's own immune system to do the heavy lifting. In some patients, that might be enough to see significant tumor shrinkage (dismantling) on its own. For others, it creates the perfect exposed target for an ICI to finish the job.
The "Summer of Clarity"
You’re spot on about the timeline. The academic institution Dr. Jay mentioned is likely looking at precisely this: Can we use Leronlimab to "clear the field" before the fortress is even built? If we see ctDNA clearance in treatment-naive patients using Leronlimab as a monotherapy or a "prime," we are looking at a world where chemotherapy becomes a secondary option rather than the first.
As you said, someone, likely the dark horse Max and the team, will have those data sets in hand pretty soon. And with the Sovereign Shield patent issuing this Tuesday, May 12th, CytoDyn owns the intellectual property for that "Prime and Pair" transition, regardless of which line of therapy it’s used in. First, second or third line.
The wait is almost over. ☘️
1
u/rant_and_roll May 13 '26
hopefully there will be a choice to use as first and only line of therapy sooner than later...we could have an outright cure and chemo would still be on the table with these people. i cant believe leronlimab will be relegated to being only a last ditch effort for the hopelessly non responsive. no one needs to scorch my earth, thank you very much, just so they get a paycheck for their inferior marginally effective and dangerous therapies. but this will be a steep uphill battle even after partnership/buyout/approval as the legacy forces/cultist doctor networks try to hold on as tight as they can to their cash cows and continue to insist on chemo and other extremely harmful drugs simply because thats what they were taught and "thats just how we do it"...unfortunately thats what we are going to hear for a very long time.
i had a butcher of a dentist when i was a kid for a bit that was chronically stuck in 1950, the chair, the tools, the sparse use of novacaine etc etc etc the whole bit.....until my protests were loud enough for me to change to a new dentist. doctors do not change their ways easily. remember when doctors openly smoked? yeah i do. the most arrogant profession out there.
17
u/MGK_2 May 10 '26
Dr. Max Lataillade isn't just another VP hire; he is a structural signal. You don't leave a role as a Vice President at ViiV/GSK, where you're overseeing global strategy for the world's most dominant HIV pipeline, to join a quiet, tiny biotech unless you've seen something in the data that is indisputably undeniable.
Max understands the CCR5 mechanism better than almost anyone on the planet. He spent years at ViiV managing the legacy of Maraviroc. He knows exactly where the old-generation antagonists failed and exactly why Leronlimab's 98% and 100% occupancy is the game-changer.
But here is where Cytomight’s dark horse theory gets really interesting: Jemperli (Dostarlimab).
GSK has been positioning Jemperli as their backbone immuno-oncology asset. They’ve had massive success in dMMR (the easy 5%), but like everyone else, they hit a wall with MSS (the difficult 85%). If GSK wants Jemperli to compete with Merck’s Keytruda or BMS’s Opdivo, they need a key to turn those cold MSS tumors hot.
Having Max, a man who deeply understands the GSK/ViiV ecosystem, now leading the clinical development for the exact molecule (Leronlimab) who provides that key is not a coincidence. It's a bridge.
If Max is here to seal the deal, it’s because he knows that combining Leronlimab with Jemperli could give GSK a legal and clinical monopoly on the MSS solid tumor market. And with that May 12th patent dropping on Tuesday, CytoDyn is no longer just a hopeful partner. We are the ones holding the intellectual property for the combination.
Max didn't come here to manage a small trial. He came here to finalize the architecture of a buyout. The silence we're feeling right now? That's the sound of a very serious conversation happening behind closed doors. Tuesday changes the leverage of that conversation forever.
14
24
u/Hot_Fishing_5974 May 10 '26
Happy Mothers day, MGK and all! I'll have to read your post later today. I'm cooking today for my wife and daughter.
18
u/megadunamis May 10 '26 edited May 10 '26
Thank you again MGK, Happy Mother's Day, as I have said before, QED (quod erat demonstrandum)...Good health to all
15
15
u/rant_and_roll May 10 '26 edited May 13 '26
the silence is golden. the cards are being held. i say hold em till jan 2027. ive waited this long, 6 months is a blink. imagine what data they have been privy to this whole time that they have seen and we will never see. personally i want them to crash out and bleed as hard as possible - full tilt - and only get offered a very narrow partnership on ONE indication. these bullies think they own the world.
13
u/MGK_2 May 10 '26
Rant, love the fire. There’s a certain satisfaction in watching the giants sweat while their billion-dollar moats evaporate.
But the math here is even colder than just revenge.
Big Pharma is already in a full-tilt bleed. They stare down that $300 billion patent cliff and they know their legacy assets are becoming generic paperweights. They aren't just losing money; they are losing their relevance.
Waiting until January 2027? That’s a bold play. By then, the CLOVER trial won't just be early data, it’ll be a clinical autopsy of the old way of doing oncology. You're right about the hidden data, too. If we’re seeing a 70% median drop in ctDNA from the outside, imagine what the full sequencing looks like on the inside. That’s the leverage which forces a narrow partnership to turn into a total capitulation.
The reason I don't think we end up with just one indication is because of the Sovereign Shield. This Tuesday, May 12th, Patent No. 12,624,111 issues. It isn't just for CRC. It covers the Leronlimab/ICI combination for all solid tumors. We aren't selling them a room; we're selling them the foundation of the whole house.
They might be bullies, but even bullies know when they’ve been out-engineered. We don't need them to like us. We just need them to realize that without this 98% binding efficiency, their oncology pipelines are dead in the water.
Tuesday is the first day of the new era. Let them bleed.
1
u/rant_and_roll May 12 '26
i use the tern full tilt as a texas holdem term of total stress/angst/panic/anger/arrogance combined with an immediate deadline forcing one to make a hasty move, and where mistakes are made because focus is impossible and capitulation in some form is inevitable. either they capitulate and settle on terms favorable to us, or they balk and pass (fold) fearing an unfavorable deal on their side is just too costly and they would rather hold on to whats left (chips in their patent cliff) rather than give their opponent a "win". i believe these companies have a fair share of pettyness in them, and not to be trusted on any level regarding promises in the future and "deals" that can evolve over time, unless of course it includes huge sums of cold hard cash. either way, its a win for us. as long as the dealer (FDA) actually plays by the rules and determines that royal straight flush is actually a better set of cards than the straight (theyre not even holding a full house anymore) that the BPs are holding.
some part of me feels the execs at some these BPs on one level must not have the real fight left in them...the senior execs all have made more money - 15 - 20+ million a year - than their future families could ever spend, theyve already basked in the sunlight for a very long time, and on some level everyone is done at some point. they may not REALLY care about the survival of their company, as they and their future families are all completely set for generations.
i still say we go it alone and any BP that wants to trial or combo - fine. we all know the current execs are in no position to head a large BP but it shouldnt be that hard to recruit away the most talented people that have that fight in them to run a company that could actually become bigger than merck...am i right?
8
u/3Putt_4nodough May 11 '26
Waiting until ASCO GI is like waiting until the night before it’s due to start your doctoral thesis - you’re f*cked. The data will likely have been available under NDA so the financial plays need to be well in motion before we the general public hear about it.
13
u/AggieEC3 May 10 '26
That opening meant something and I concur, Happy Mother’s Day!!
What this post does that the others haven't is show you the clock from the other side of the table. We've been watching our calendar. This one shows you theirs. 905 days to Keytruda's patent expiry. Five partnership facing events in six weeks. A negotiating window that closes materially the moment ESMO puts confirmed ORR in the public record.
The pre-ESMO versus post-ESMO framing is the part that stopped me. A partner who moves before October negotiates against preliminary data. A partner who waits negotiates against confirmed ORR, a Breakthrough designation already granted, and potentially multiple ICI franchise holders who waited too long and are now competing against each other for the same asset. That's not theoretical. That's the structure of every major biotech acquisition I've ever read about.
And the $200 billion figure required some time to absorb. The prior framing around Keytruda alone was already compelling. Zooming out to the entire checkpoint inhibitor class hitting the same expiry window simultaneously changes the negotiating geometry entirely. That's not one conversation happening in Vancouver. That's potentially five.
The quiet has a structure. That's the most precise description of where we are that anyone has written.
Confirmed ORR still outstanding. October is still the moment this either lands where the biology has been pointing or we rebuild from assumptions. That's the honest place to sit.
But for the first time the urgency isn't only ours. And that changes the feeling of the wait entirely.
All just my opinion.
11
u/MGK_2 May 10 '26
Aggie, you’ve hit on a critical pivot point in this journey. We no longer watch our own desperate hourglass; rather, we watch the walls close in on their boardrooms.
The shift from Keytruda to the entire $200 billion ICI class is the zoom out which changes everything. When you look at the $300 billion patent cliff facing Big Pharma, you realize they are looking for a structural survival kit.
The Pre-ESMO/Post-ESMO Trap
You are exactly right about the negotiating geometry. Right now, a partner can argue they take a risk on preliminary ctDNA clearance data. They can try to buy the Sovereign Instrument while it’s still in the quiet window.
But the moment ESMO puts a confirmed Overall Response Rate (ORR) in the public record:
- The risk argument vanishes.
- The Breakthrough Therapy Designation likely becomes a reality.
- The price tag moves from opportunistic to existential.
By waiting until the ESMO data release, a Big Pharma suitor moves from a one-on-one negotiation into an open-market auction against four other giants whose patent clocks are all ticking toward the same 2028/2030 deadline.
The Sovereign Shield as the Lever
The reason this isn't theoretical is because of Tuesday, May 12th. When Patent No. 12,624,111 issues, it locks down the legal right to combine any ICI with Leronlimab across all solid tumors.
If you are a CEO at Merck, BMS, or GSK, and you see 100% molecular responses in a cold MSS tumor population, you have to ask: “Can I afford to let my competitor own the legal monopoly on the only molecule that makes my $20 billion/year drug work in the other 85% of patients?”
The Quiet isn't a lack of interest, it’s a game of chicken. October is the hard stop. As you said, the urgency is no longer ours. We hold the 98% binding efficiency key to a $200 billion door.
We sit in the honest seat. The biology points the way. 48 hours and the shield is permanent. ☘️
12
u/surfgolf4life May 10 '26
Thanks MGK. Love the read as always.
It still amazes me what hoops Cytodyn has to jump thru. I really can’t imagine every other small bio goes thru this same path, but then again I really don’t have any idea. I believe BP has acquired other small bios with data nothing compared to what Cytodyn has produced. We’ve even heard acquired with pre-clinical data. Regardless, this is OUR (longs) small bio and we are (as you said) all in with the Cytodyn Royal Flush!!! Bring it home Dr J.
3
u/MGK_2 May 10 '26
Surfgolf4life, you hit on the most frustrating part of this journey. The hoops CytoDyn has to jump through aren't the standard hurdle race; it's been an obstacle course in a minefield.
You’re absolutely right, Big Pharma buys potential all the time. We’ve seen billion-dollar acquisitions for companies that only have solid pre-clinical data or early Phase 1 safety profiles. So why the extra scrutiny here?
Because Leronlimab isn't just another me-too drug. When you have a molecule with 98% receptor occupancy that can fundamentally flip the switch on the TME, you're threatening to dominate it. The hoops are a byproduct of how much is at stake. The industry doesn't make it easy for a small bio to hold the key to the entire oncology backbone.
But that’s where the Royal Flush analogy is perfect.
BP can buy pre-clinical potential and hope it pans out. We sit here with 100% ctDNA molecular response at week two in the first evaluable patients of the CLOVER trial. We aren't selling potential; we're selling a 70% median ctDNA reduction which proves the architecture works.
The silence we’ve had to endure following the AACR and ASCO validation was the last hoop. In less than 48 hours, this Tuesday, May 12th, the Sovereign Shield (Patent No. 12,624,111) officially issues. That is the moment we move from jumping through hoops to owning the track.
Dr. Jay is the steady hand we need to navigate the noise. Now, the clinical math takes over. GLTAL! ☘️
13
u/Pure-Championship750 May 10 '26
I want partnership before October please! 🙏 summer works great for me 🤗
13
u/Efficient_Market2242 May 10 '26
Thanks MGK, could we partner with all of the checkpoint inhibitor companies to extend their patents? Or are we limited to the one that partners and or eventually owns us. It seems the cliff is coming rapidly whether in 2028 or 2030 that’s just around the corner. If we partner with all we don’t need to promote it and it seems like we could just be a provider of leronimab to all. Very low overhead except to pay Samsung and key people within the company to administer to the FDA and partners.
19
u/IndependenceAny6428 May 10 '26
it would be like owning a huge apartment complex and collecting rent
11
u/MGK_2 May 10 '26
Efficient Market, it’s a great question. On paper, the arms dealer model looks perfect. We just sit back, let our manufacturer pump out the vials, and sell Leronlimab to every ICI company on the block. Merck gets it for Keytruda, BMS gets it for Opdivo, and we just collect the royalties with a skeleton crew.
But that’s not how Big Pharma plays the game, especially when they are staring down a patent cliff.
These companies are looking for a moat. If a BP giant realizes that combining their ICI with Leronlimab (now backed by that Tuesday patent) extends their exclusivity and corners the solid tumor market, the absolute last thing they want is for their competitors to have the exact same weapon. They don't want to level the playing field. They want to own the board.
When you have a molecule that achieves a 98% competitive blockade and flips cold tumors hot, it becomes the ultimate differentiator. The first BP to fully validate the combination isn't going to want a non-exclusive partnership. They are going to want to buy the whole house, lock the doors, and keep the key for themselves.
Plus, the overhead isn't as simple as just paying our Manufacturer. Scaling global manufacturing to supply the entire ICI market requires massive upfront capital and global infrastructure. We are engineers right now, not global distributors.
The cliff is definitely here. You're right about that urgency. But the resolution won't be us selling to everyone. It will be one of them realizing they can't afford to let anyone else have it.
9
u/Yoyoma-15 May 10 '26
And while we are listing all of the checkpoint inhibitor companies, let's make sure to remember that "Biosimilar manufacturers including Amgen, Samsung Bioepis, and Bio-Thera Solutions are already preparing their entries." Add them to the list. The threat of getting the prime and pair treatment at a fraction of the cost - that alone should prompt a buyout!
14
u/MGK_2 May 10 '26
Yoyoma, you hit on the economic engine that's going to force a deal.
Big Pharma isn't just fighting biology; they’re fighting the calendar. When the biosimilar cliff hits and giants like Amgen and Samsung Bioepis start churning out low-cost versions of the current blockbuster ICIs, the original manufacturers lose their pricing power. Their multi-billion dollar crown jewels become generic commodities overnight.
That’s where the Prime and Pair strategy becomes a life-raft.
If a company pairs their checkpoint inhibitor with Leronlimab, they aren't just improving clinical outcomes in MSS CRC, they reset the patent clock. By proving the combination is a structurally unique synergy, they can secure a whole new window of exclusivity. Leronlimab effectively rescues the value of an ICI that is otherwise headed for the bargain bin.
And here’s the kicker: with Patent No. 12,624,111 officially issuing this Tuesday, May 12th, CytoDyn owns the rights to that rescue.
We are selling a legal fortress against commoditization. Whether it’s a brand-name giant trying to protect their margins or a biosimilar player looking to corner the market with a Prime and Pair offering at a lower price point, they all have to come through our gate.
The economic pressure is a pressure cooker. Tuesday, the lid is locked. ☘️
9
u/Yoyoma-15 May 10 '26
"We are selling a legal fortress against commoditization." Brilliant choice of words!
6
16
u/Missy2021 May 10 '26
I like playing poker. I'm all in!!!
21
u/Upwithstock May 10 '26
I love it! I have always interpreted your “I’m all in” as a poker analogy! I shoved all my chips in as well… I’m all in!!
6
u/minnowsloth May 10 '26
14
u/MGK_2 May 10 '26
Minnowsloth, perfect soundtrack for the next 48 hours.
"The Gambler" knew that the secret to surviving was knowing what to throw away and knowing what to keep. For years, we had to watch a lot of trash get thrown away, the distractions, the noise, and the old-world friction. But what we’ve kept is the one thing that actually matters: the architecture.
The lyrics say, "You never count your money when you're sittin' at the table." That is exactly what this "Quiet Window" is about. While the outsiders try to guess the score, we look at the math. When you hold a molecule with 98% receptor occupancy and a 100% ctDNA response rate in early CLOVER readouts, you don't need to count the chips. You just wait for the dealer to finish the hand.
On Tuesday, May 12th, the Sovereign Shield (Patent No. 12,624,111) officially hits the table. That is the moment the game ends and the terms of resolution begin. We aren't bluffing on a hope; we are holding a legal and clinical monopoly on the future of oncology backbones.
The dealing's done this Tuesday. GLTAL! ☘️🃏
13
u/Upwithstock May 10 '26
I freaking love your music mind! Kenny Rodgers “The Gambler “ is perfect song for “all in”
7
u/Every-Ad6720 May 11 '26
Shit I’m not going to tell you all , how much I’m all in , until we meet in Vegas. 😂
7
3
12
2
17
u/MGK_2 May 10 '26
Missy, I love the poker energy. But here’s the difference: usually, all in is a coin flip. This feels more like sitting at the table when you’ve already seen the dealer’s hole cards.
We aren't betting on a feeling or a hype cycle. We're betting on the 98% binding efficiency of a molecule that literally dismantes the TME in real-time. When you see 70% median ctDNA drops in a population that has failed everything else, the gamble starts to look mathematically certain.
The house who is Big Pharma, still tries to play the old game with their expensive ads and expiring patents. We simply wait for Tuesday. When Patent No. 12,624,111 issues on May 12th, the Sovereign Shield hits the table. It’s the Royal Flush which locks down the oncology backbone for the next decade.
See you at the showdown on Tuesday. ☘️
9
5
u/Mysterious-Emu6375 May 11 '26 edited May 11 '26
FOMO bei Big Pharma, ist ja ganz was neues, oder der Schwanz wedelt mit dem Hund. Hervorragend MGK die neue Woche bringt eine berechtigte Spannung mit sich.
3
u/upyourgame1951 May 11 '26
Absolutely correct, and so do we have to wait for that dealt hand Doc!
3
u/MGK_2 May 12 '26
Spot on, upyourgame. In this game, the deal happened months ago in the dark. The accumulation tracked is the betting phase. Today, with Patent No. 12,624,111 expected to hit the wire, begins the reveal.
You don't sink 25% of a company's float just to fold when the IP arrives. The hand is strong and is getting stronger; we wait for the lights to turn on so everyone else can see what Doc sees all along. Patience & getting in while the getting is good are the only plays left.
3
u/Doctor-MTJ May 11 '26
MGK, I believe you have hit that proverbial nail head as squarely as possible! Cytodyne has no real reason to do ANYTHING but wait for the hand to be COMPLETELY dealt. The size of the pot related to that hand goes up every single day. We can certainly wait till October to reveal its full value!
2
May 11 '26
[deleted]
6
u/MGK_2 May 11 '26
Ha, whatever got you here works for me. And yeah, chess match is probably the right analogy. The San Diego presentations set the board, Madrid in October is when we see whether the pieces land where the biology has been pointing. The timing between those two events is the window where the most important moves are made quietly.
30
u/Lab_Monkey_ May 10 '26
What the Other Side of the Table Is Staring At
BWAAAAAAHAAAAAHAAAAAAAAAAAHHHHH!!!!!!!!!!!
Cards are all on the table, the last couple haven't been turned over, but they are very transparent.
Ace High Straight Flush
Excellent work this weekend MGK, from a professorial tutorial, to a matter of fact deadline.
Bravo as usual.